Cargando…

P865: TECLISTAMAB IN COMBINATION WITH LENALIDOMIDE IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA IN THE PHASE 1B MULTICOHORT MAJESTEC-2 STUDY

Detalles Bibliográficos
Autores principales:	Tan, Carlyn, Searle, Emma, Anguille, Sébastien, Bhutani, Manisha, Biran, Noa, Boyd, Kevin, Cowan, Andrew, Matous, Jeffrey, Perrot, Aurore, Berdeja, Jesus, Janowski, Wojciech, Popat, Rakesh, Quach, Hang, Schroeder, Mark, Wong, Sandy W, Vishwamitra, Deeksha, Guo, Yue, Niu, Zhuolu, Larsen, Julie, Chen, Lingling, Banerjee, Arnob, Touzeau, Cyrille
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431062/ http://dx.doi.org/10.1097/01.HS9.0000970364.16259.0e

Ejemplares similares

P30 SINGLE COHORT RESULTS FROM MAJESTEC-2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
por: Searle, E., et al.
Publicado: (2023)

S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
por: Offner, Fritz, et al.
Publicado: (2023)

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1
por: Miao, Xin, et al.
Publicado: (2023)

P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Mateos, M. V., et al.
Publicado: (2022)

P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY
por: Bhutani, Manisha, et al.
Publicado: (2023)

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: van de Donk, N., et al.
Publicado: (2023)

P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Sidana, Surbhi, et al.
Publicado: (2023)

P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Martínez-López, J., et al.
Publicado: (2022)

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
por: Popat, R., et al.
Publicado: (2022)

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Popat, R, et al.
Publicado: (2022)

Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Teclistamab: First Approval
por: Kang, Connie
Publicado: (2022)

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY
por: Rodriguez-Otero, P, et al.
Publicado: (2022)

Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Teclistamab impairs detection of BCMA CAR-T cells
por: Glatte, Bettina, et al.
Publicado: (2023)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS
por: Frerichs, Kristine, et al.
Publicado: (2023)

P962: COMMERCIAL TECLISTAMAB IN ANTI-BCMA THERAPY EXPOSED RELAPSED REFRACTORY MULTIPLE MYELOMA PATIENTS: THE MSKCC EXPERIENCE.
por: Firestone, Ross, et al.
Publicado: (2023)

865. Acanthamoeba Disease Associated With the Practice of Nasal Rinsing in Immunocompromised Patients
por: Cope, Jennifer, et al.
Publicado: (2018)

Expanding role of lenalidomide in hematologic malignancies
por: Ghosh, Nilanjan, et al.
Publicado: (2015)

High-Quality Draft Genome Sequence of Pseudomonas reidholzensis Strain CCOS 865(T)
por: Rutz, Dominik, et al.
Publicado: (2019)

First report of teclistamab in a patient with relapsed AL amyloidosis and multiple myeloma
por: Leung, Nelson, et al.
Publicado: (2023)

Multicohort analysis of the maternal age effect on recombination
por: Martin, Hilary C., et al.
Publicado: (2015)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

P865: Revised letter of intent for a high - sensitivity study of charm and beauty decays
por: Isenhower, L D, et al.
Publicado: (1993)

Elastic scattering of negative kaons on polarized protons between 865 and 1330 MeV/c
por: Albrow, Michael G, et al.
Publicado: (1971)

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody
por: Pan, Darren, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Polarization in elastic $\pi^{-}p$ scattering at 16 momenta between 865 and 2732 MeV/c
por: Albrow, M G, et al.
Publicado: (1972)

Inflammatory biomarkers and motoric cognitive risk syndrome: Multicohort survey
por: Groeger, Justina L, et al.
Publicado: (2022)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023)

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
por: Brosseau, C, et al.
Publicado: (2014)

Healthberry 865(®) and a Subset of Its Single Anthocyanins Attenuate Oxidative Stress in Human Endothelial In Vitro Models
por: Ockermann, Philipp, et al.
Publicado: (2022)

865. Same Shift Susceptibility Testing of Cefepime-Taniborbactam and Cefiderocol Using The Selux Next-Generation Phenotyping System
por: Jimenez, David, et al.
Publicado: (2023)

Determining the timing of pubertal onset via a multicohort analysis of growth
por: Syrjälä, Essi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hln3fvc9rmigicfdnmdp6a84ul